NCT00657891View on ClinicalTrials.gov

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

PHASE4CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Asthma

Interventions

DRUG

Omalizumab

0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously

DRUG

Placebo

Placebo Injection

Trial Locations (1)

68131

Creighton University Medical Center, Omaha

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Creighton University

OTHER